Lab Reference Library / MSH (Alpha-Melanocyte Stimulating Hormone) Detox, Mold & CIRS

MSH (Alpha-Melanocyte Stimulating Hormone)

MSH · Alpha-MSH · Alpha-Melanocyte Stimulating Hormone

Reference range, optimal functional medicine levels, and why MSH below 35 pg/mL is the most consistent single finding in CIRS, how biotoxin-driven MSH depletion simultaneously disrupts sleep, pain modulation, mucosal immunity, and TGF-beta1 regulation, and why MARCoNS eradication is required before MSH can recover.

CIRS Master MarkerSpecialty Testing

Low CIRSBelow 35 pg/mL

Reference35 to 81 pg/mL

Optimal60 to 81 pg/mL

Unitspg/mL

← Back to Lab Reference Library

Category: Detox, Mold & CIRS | Also known as: Alpha-MSH, Alpha-Melanocyte Stimulating Hormone, Melanocortin

1. What This Test Measures

Alpha-MSH (alpha-melanocyte stimulating hormone) is a 13-amino acid neuropeptide cleaved from proopiomelanocortin (POMC) in the pituitary gland, hypothalamus, and peripheral immune cells. It is not merely a pigmentation signal but a master regulatory peptide governing inflammation resolution, pain modulation, sleep architecture, mucosal immunity, reproductive hormone support, antidiuretic hormone regulation, and pituitary function across multiple axes. MSH exerts its effects by binding five melanocortin receptor subtypes (MC1R through MC5R) expressed in skin, brain, immune cells, adrenal glands, gut, and reproductive organs, producing a coordinated anti-inflammatory and homeostatic response across all these systems simultaneously.

In the hypothalamus, MSH binds MC4R to regulate energy balance, body weight, and feeding behavior. In the spinal cord dorsal horn, MSH activates MC4R on inhibitory interneurons to reduce pain signal transmission, explaining the pain amplification seen when MSH is depleted. In mucosal immune tissues, MSH promotes secretory IgA production and regulates mast cell degranulation, providing frontline mucosal defense. In peripheral immune cells, MSH suppresses NF-kB activation and the downstream production of IL-1beta, TNF-alpha, and IL-6, acting as a natural immunosuppressive brake on excessive inflammation.

In the Shoemaker CIRS framework, MSH is the single most important regulatory marker and its depletion is found in approximately 95% of confirmed CIRS patients. The mechanism: biotoxin exposure activates innate immune pattern recognition receptors, producing a cytokine surge (particularly IL-1beta, TNF-alpha, and TGF-beta1) that suppresses hypothalamic POMC processing, reducing MSH output. As MSH falls, the regulatory systems it controls deteriorate in parallel: TGF-beta1 rises, sleep architecture degrades, pain amplification worsens, mucosal immunity weakens, and the HPA axis becomes dysregulated. MSH depletion is simultaneously a consequence of biotoxin immune activation and a perpetuator of it, making MSH restoration the ultimate goal of the CIRS treatment sequence.

2. Reference Range and Optimal Levels

MSH Level	Interpretation
Below 35 pg/mL	Low: found in approximately 95% of confirmed CIRS patients; all downstream MSH-regulated systems affected
35 to 40 pg/mL	Borderline: evaluate with other CIRS markers and exposure history; may represent early or partially treated CIRS
40 to 60 pg/mL	Low-normal: adequate for basic regulatory function; optimal is the upper portion of the range
60 to 81 pg/mL	Optimal: full hypothalamic regulatory capacity; all downstream systems adequately supported
Above 81 pg/mL	Elevated: uncommon; possible POMC-secreting tumor if markedly elevated; evaluate clinically

MSH testing requires a laboratory experienced with POMC-derived peptide assays. Not all commercial laboratories offer validated MSH testing; National Jewish Health and a small number of specialty laboratories provide the assay used in CIRS research. Results must be interpreted in the context of the full CIRS panel. MSH can be falsely low from improper specimen handling (MSH degrades rapidly at room temperature); specimens should be kept on ice and processed promptly.

3. What Low MSH Produces: The Multi-System Cascade

Neurological and Pain Effects

Non-restorative sleep: MSH regulates hypothalamic sleep circuits through MC4R signaling in the suprachiasmatic nucleus and sleep-promoting neurons in the ventrolateral preoptic area; low MSH disrupts slow-wave and REM sleep architecture, producing the characteristic CIRS sleep pattern where patients sleep 9 to 11 hours and wake exhausted with unrefreshing, dream-fragmented sleep and morning cognitive fog
Pain amplification and allodynia: MSH activates descending pain inhibitory pathways through MC4R on spinal cord inhibitory interneurons; without adequate MSH signaling, the descending inhibitory pathway is weakened, allowing pain signals to be amplified at the dorsal horn; patients experience widespread achiness, tenderness to light touch, and muscle pain without clear structural pathology
Cognitive impairment and brain fog: MSH has direct neuroprotective effects through MC4R signaling in the hippocampus, prefrontal cortex, and basal ganglia; its depletion reduces synaptic plasticity, working memory capacity, processing speed, and executive function; patients describe word-finding difficulty, short-term memory loss, inability to concentrate, and a sense of cognitive dissociation
Mood dysregulation: MSH modulates HPA axis reactivity and mesolimbic dopamine signaling; low MSH amplifies the cortisol stress response and reduces the reward circuitry engagement that normally provides emotional resilience; anxiety, irritability, emotional lability, and anhedonia are common

Immune and Hormonal Effects

TGF-beta1 disinhibition: MSH is the primary hypothalamic brake on TGF-beta1 production through its regulatory effect on immune cell MC1R signaling; when MSH falls, TGF-beta1 rises unchecked, driving the immunosuppressive and pro-fibrotic components of CIRS
Reduced mucosal immunity and MARCoNS vulnerability: MSH supports secretory IgA production in nasal, gut, and bronchial mucosa through MC1R signaling on mucosal immune cells; low MSH reduces sIgA-mediated protection, creating the mucosal vulnerability to MARCoNS (multiply-antibiotic-resistant coagulase-negative staphylococci) deep nasal colonization that perpetuates the CIRS inflammatory cycle
ADH dysregulation and polydipsia: MSH and ADH (antidiuretic hormone) are both POMC-derived peptides and share regulatory circuits in the posterior pituitary; MSH depletion often accompanies ADH dysregulation, producing the CIRS-associated polydipsia (excessive thirst), polyuria, and electrolyte instability that compounds the clinical picture
Androgen suppression: MSH supports Leydig cell function in men through MC2R signaling; low MSH in male CIRS patients often correlates with reduced testosterone and DHEA, compounding the fatigue, cognitive impairment, and poor recovery characteristic of CIRS
Leptin resistance: MSH normally suppresses leptin signaling at the hypothalamic level; low MSH allows leptin to act unopposed, promoting the leptin resistance and central obesity sometimes seen in CIRS despite normal or low caloric intake

4. The MARCoNS Connection: Why MSH Cannot Recover Without Nasal Treatment

MARCoNS (multiply-antibiotic-resistant coagulase-negative staphylococci) is found in the deep nasal passages of approximately 80% of CIRS patients with MSH below 35 pg/mL. This is not coincidental. MARCoNS produces hemolysins (alpha and beta toxins) that cleave MSH directly at the nasal mucosal surface and through systemic hemolysin release, continuously driving MSH below the threshold needed for immune regulation. Even after a CIRS patient has eliminated biotoxin exposure and completed binder therapy to reduce C4a and TGF-beta1, MSH will not recover as long as MARCoNS persists because the hemolysin-mediated MSH cleavage continues uninterrupted.

The clinical consequence is that patients who complete binder therapy and leave water-damaged environments but skip MARCoNS eradication plateau in their recovery: C4a and TGF-beta1 may partially improve, but MSH remains low, sleep and pain remain disrupted, and immune function remains impaired. Nasal culture with sensitivity testing (not a standard nasal swab but a deep nasal culture for coagulase-negative staph with antibiotic resistance profiling) is required to confirm MARCoNS presence and guide treatment. BEG spray (Bactroban-Bacitracin-EDTA-Gentamicin compounded nasal spray) is the primary treatment; EDTA nasal spray disrupts the biofilm that protects MARCoNS from antibiotic action.

5. The CIRS Treatment Sequence and MSH Recovery

MSH does not recover until every upstream contributor is addressed sequentially. The Shoemaker 11-step protocol is specifically ordered to create the biochemical conditions for MSH restoration at each stage: exposure elimination allows the primary biotoxin stimulus to stop; binder therapy reduces recirculating biotoxins; MARCoNS eradication stops hemolysin-mediated MSH cleavage; androgen correction restores hormonal support for MSH production; ADH correction stabilizes osmolality and pituitary regulatory function; MMP-9 reduction protects the blood-brain barrier that allows regulatory signals to reach the hypothalamus; C4a and TGF-beta1 normalization removes the cytokine suppression of hypothalamic POMC processing.
VIP nasal spray as the final MSH-restoring intervention: vasoactive intestinal polypeptide (VIP) administered as a compounded intranasal spray in steps 10 and 11 of the Shoemaker protocol directly stimulates hypothalamic MSH production through VPAC1 and VPAC2 receptor signaling; VIP also reduces MMP-9, raises VEGF, reduces pulmonary artery pressure, and inhibits pro-inflammatory cytokine production; it is the intervention that restores MSH when all upstream factors have been addressed; VIP cannot be used before earlier steps are complete because its half-life (approximately 2 minutes) is further shortened by the complement-rich inflammatory environment of active CIRS
Monitoring MSH through treatment: MSH should be measured at baseline and every 60 to 90 days through the treatment sequence; a rising MSH toward 40 to 60 pg/mL confirms that the upstream treatment steps are working; persistent MSH below 35 pg/mL despite apparent protocol completion signals that a missed exposure source, untreated MARCoNS, or incomplete upstream step is blocking recovery

6. Supporting MSH Recovery

Essential Protocol Steps

Confirmed biotoxin exposure elimination: ERMI dust sampling of home and workplace; VCS testing to monitor neurological status; leave water-damaged environments before treatment
Cholestyramine or welchol binder therapy: interrupts enterohepatic biotoxin recirculation that drives cytokine-mediated MSH suppression
MARCoNS culture and eradication: deep nasal culture at a laboratory experienced with coagulase-negative staph resistance profiling; BEG spray or EDTA-based biofilm disruption; repeat culture to confirm eradication before advancing protocol
VIP nasal spray at appropriate protocol stage: compounded VIP (50mcg per puff, 4 puffs four times daily) used only after upstream steps are completed; monitor MSH, MMP-9, VEGF, and TGF-beta1 response

Nutritional Support for MSH Production

Adequate protein and amino acid sufficiency: MSH is a peptide requiring adequate precursor amino acid availability; protein intake of at least 1.2g per kg body weight daily; specific attention to phenylalanine and tyrosine as POMC precursors
Vitamin D optimization (60 to 80 ng/mL): vitamin D receptor signaling supports hypothalamic POMC expression; deficiency impairs MSH production; supplementation to optimal range is a prerequisite for MSH recovery
Zinc adequacy: zinc is required for POMC processing enzymes including prohormone convertase 1 and 2; zinc deficiency impairs MSH cleavage from POMC; target serum zinc 80 to 110 mcg/dL
Phosphatidylserine (400mg daily): reduces cortisol response to stress; chronic HPA hyperactivation from CIRS suppresses POMC processing; blunting the cortisol spike with phosphatidylserine reduces the cortisol-mediated inhibition of MSH production
Magnesium glycinate (400 to 600mg at bedtime): supports slow-wave sleep where MSH-dependent regulatory processes are most active; reduces HPA axis hyperreactivity that suppresses POMC

Sleep and Lifestyle Foundations

Sleep architecture repair: MSH regulates sleep and is regulated by it in a bidirectional relationship; improving sleep quality through blue light reduction, consistent sleep timing, dark cool sleeping environment, and treatment of underlying sleep apnea creates the slow-wave sleep that allows MSH-dependent restorative processes; melatonin (0.5 to 3mg) supports circadian alignment
Low amylose diet: avoidance of high-amylose starches reduces leptin surges that suppress MSH through competitive MC4R antagonism at the hypothalamus; emphasize non-starchy vegetables, lean protein, nuts, and healthy fats
Moderate exercise: gentle to moderate aerobic activity supports hypothalamic regulatory function and reduces the systemic inflammatory burden that suppresses POMC; avoid overtraining, which spikes cortisol and IL-6, both of which suppress hypothalamic MSH production
Stress management: chronic psychological stress activates HPA axis and sympathetic nervous system in ways that directly suppress hypothalamic POMC processing; mindfulness, breathwork, and parasympathetic activation support MSH recovery through HPA axis regulation

7. Related Lab Tests

TGF-beta1Inversely Regulated by MSH; the Primary Pro-Fibrotic Consequence of MSH Depletion

→

C4aComplement Activation; the Most Sensitive Upstream CIRS Marker

→

MMP-9Blood-Brain Barrier Disruption; Neuroinflammation Companion Marker

→

VIPRestores MSH at Final Protocol Stage; Addresses Pulmonary and Immune Regulation

→

ACTHShares POMC Precursor with MSH; HPA Axis Companion

→

Secretory IgAMucosal Immunity Dependent on MSH; Low in CIRS

→

8. Clinical Perspective

Clinical Perspective

MSH is the lab value that transforms a seemingly impossible clinical picture into a coherent, mechanistically connected illness. When a patient comes in with non-restorative sleep, widespread pain, cognitive fog, recurrent sinus infections, temperature dysregulation, excessive thirst, mood instability, and profound fatigue that has been attributed to fibromyalgia, chronic fatigue syndrome, depression, and psychosomatic illness over the preceding five years, and their MSH is 14 pg/mL alongside C4a of 38,000 and TGF-beta1 of 22,000, every one of those symptoms has a direct mechanistic explanation through MSH depletion and its downstream cascade. That is not six separate problems requiring six separate treatments. It is one regulatory peptide whose depletion dismantles every system it governs simultaneously. The treatment goal becomes singular: restore MSH by addressing every upstream factor that is preventing its recovery. That reframe changes everything for these patients, because they have been told for years that their symptoms do not make sense. When you show them the mechanism on paper and explain that MSH governs all of those systems, and that the treatment sequence is specifically designed to restore it, many of them experience genuine relief just from having a coherent explanation for the first time. The clinical improvement follows when we work through the protocol properly.

Brian Lamkin, DO | Founder, The Lamkin Clinic | Edmond, Oklahoma

9. Frequently Asked Questions

Why is MSH below 35 pg/mL so significant in CIRS?

MSH below 35 pg/mL is the most consistent single finding in CIRS, present in approximately 95% of confirmed cases. At this level, all MSH-regulated systems are inadequately supported: sleep architecture degrades, pain modulation fails, mucosal immunity is impaired, TGF-beta1 rises unchecked, and the MARCoNS colonization vulnerability that perpetuates the cycle develops. The clinical picture of a patient with MSH of 14 pg/mL is not six separate problems; it is one depleted regulatory peptide producing parallel dysfunction across every system it governs.

Why does MSH not recover on its own after leaving a moldy building?

In HLA-DR-susceptible patients, biotoxins cannot be cleared through normal antibody-mediated immune mechanisms and undergo continuous enterohepatic recirculation. Each cycle stimulates innate immune activation and cytokine-mediated POMC suppression, maintaining low MSH. Compounding this, MARCoNS colonization that develops in the context of low MSH produces hemolysins that directly cleave MSH at the nasal mucosal surface. Without binder therapy to interrupt recirculation and MARCoNS eradication to stop hemolysin-mediated cleavage, MSH remains suppressed indefinitely even after the patient leaves the water-damaged environment.

Can MSH be supplemented directly to restore levels?

MSH itself is not available as an approved clinical supplement or pharmaceutical. The closest clinical intervention is VIP (vasoactive intestinal polypeptide) nasal spray, used in the final stages of the Shoemaker CIRS protocol, which stimulates hypothalamic MSH production indirectly through VPAC receptor signaling. Alpha-MSH peptide analogs exist in research settings but are not standard clinical treatments. Addressing the upstream causes through the full sequential CIRS protocol is the only evidence-based approach to MSH restoration in biotoxin illness.

What is the relationship between MARCoNS and MSH?

MARCoNS (multiply-antibiotic-resistant coagulase-negative staphylococci) colonize the deep nasal passages in approximately 80% of CIRS patients with MSH below 35 pg/mL. The low-MSH mucosal immune environment creates vulnerability to this colonization. Once established, MARCoNS produces alpha and beta hemolysins that directly cleave and inactivate MSH molecules in the nasal mucosa and systemically. This creates a reinforcing cycle: low MSH allows MARCoNS colonization, and MARCoNS colonization keeps MSH low. Breaking this cycle requires deep nasal culture-directed eradication with BEG spray before MSH can recover.

How is MSH measured and what can affect the result?

MSH is measured from serum by immunoassay. It is a labile peptide that degrades rapidly at room temperature; specimens must be kept cold and processed promptly. Not all commercial laboratories offer validated MSH testing; specialty laboratories experienced with POMC-derived peptide assays should be used. Results are reported in pg/mL and interpreted alongside the full CIRS panel. Elevated cortisol (from acute stress or exogenous corticosteroids), leptin excess, and chronic cytokine exposure can all suppress MSH acutely and should be considered when interpreting unexpectedly low results.

Content authored and clinically reviewed by Brian Lamkin, DO, founder of The Lamkin Clinic in Edmond, Oklahoma. Brian Lamkin, DO has 25+ years of experience in functional and regenerative medicine. This page reflects current functional medicine practice standards and is updated as new clinical evidence becomes available.

MSH below 35 pg/mL explains why CIRS produces simultaneous deterioration across sleep, pain, immunity, cognition, and hormonal regulation. Restoring it is the ultimate goal of the treatment sequence.

MSH is the central regulatory marker of CIRS. Schedule a consultation for a comprehensive CIRS evaluation including the full Shoemaker panel and a structured recovery plan.

Schedule a Consultation

Medical Disclaimer: This content is provided for educational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Lab interpretation should always be performed in clinical context by a qualified healthcare provider. Reference ranges and optimal targets may vary based on individual patient history, clinical presentation, and laboratory methodology. Schedule a consultation to discuss your specific results with Dr. Lamkin.